The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 31 January 2006, www.theannals.com, DOI 10.1345/aph.1G409.
 The Annals of Pharmacotherapy: Vol. 40, No. 2, pp. 290-294. DOI 10.1345/aph.1G409
© 2006 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow For Our Patients
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Levy, H. B.
Right arrow Articles by Kohlhaas, H. K
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Levy, H. B.
Right arrow Articles by Kohlhaas, H. K

DRUG INFORMATION ROUNDS

Considerations for Supplementing with Coenzyme Q10 During Statin Therapy

Hedva Barenholtz Levy, PharmD BCPS CGP

Director, HbL PharmaConsulting; Lecturer, University of Missouri, St. Louis, MO; Adjunct Instructor of Pharmacy Practice, St. Louis College of Pharmacy

Heather K Kohlhaas

Pharmacy Student, St. Louis College of Pharmacy

Reprints: Dr. Levy, 9648 Olive Blvd., Ste. 309, St. Louis, MO 63132-3002, fax 314/994-9409, Hedva{at}hblpharm.com

OBJECTIVE: To review the literature concerning the effects of statin use on coenzyme (Co) Q10 concentrations and explain the rationale behind considering CoQ10 supplementation.

DATA SOURCES: A MEDLINE search was conducted through January 2006. Search terms included ubiquinone, coenzyme Q10, HMG-CoA reductase inhibitors, statins, myotoxicity, and clinical trials.

DATA SYNTHESIS: Statin therapy reduces blood CoQ10 concentrations. Studies exploring how this affects the development of myotoxicity have been small and dissimilar, thus limiting the ability to draw strong conclusions. Isolated studies suggested that statins induce mitochondrial dysfunction, but the clinical implications of this effect are limited. Limited data suggest that patients with familial hypercholesterolemia, heart failure, or who are over 65 years of age might represent at-risk populations who would benefit from CoQ10 supplementation.

CONCLUSIONS: Routine CoQ10 supplementation for all patients taking statins to prevent myotoxicity is not recommended. However, certain subpopulations might be at risk and warrant further study.

Key Words: coenzyme Q10, HMG-CoA reductase inhibitors, statins, ubiquinone

Published Online, January 31, 2006. www.theannals.com, DOI 10.1345/aph.1G409


This article has been cited by other articles:


Home page
 FASEB J.Home page
K. Sakamoto, T. Honda, S. Yokoya, S. Waguri, and J. Kimura
Rab-small GTPases are involved in fluvastatin and pravastatin-induced vacuolation in rat skeletal myofibers
FASEB J, December 1, 2007; 21(14): 4087 - 4094.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2006 by Harvey Whitney Books Company.